Medical Policy
Elzonris (tagraxofusp-erzs) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Table of Contents
• Policy: Commercial
• Coding Information
• Information Pertaining to All Policies
• Policy: Medicare
• Description
• References
• Authorization Information
• Policy History
• Endnotes

Policy Number: 009
BCBSA Reference Number: N/A
NCD/LCD: N/A

Related Policies
Elzonris (tagraxofusp-erzs) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Prior Authorization Request Form, #928

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity
Medicare HMO BlueSM and Medicare PPO BlueSM Members

The use of Elzonris (tagraxofusp-erzs) for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in patients 2 years and older may be considered MEDICALLY NECESSARY when ALL of the following criteria are met:

• Confirmed diagnosis of BPDCN; AND
• Must be prescribed by or in consultation with an oncologist or hematologist; AND
• The patient has an ECOG performance score of 0-2; AND
• Documentation of serum albumin is greater than or equal to 3.2 g/dL, prior to the first dose of initial treatment cycle; AND
• Initial treatment cycle MUST be administered in an inpatient setting and patient will be monitored for at least 24 hours after last infusion:
  o Subsequent treatment cycles may be administered in an appropriate outpatient setting.

Elzonris (tagraxofusp-erzs) is considered INVESTIGATIONAL for all other indications, including but not limited to acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelofibrosis.

Continuation of Elzonris (tagraxofusp-erzs) will be approved annually at the FDA-approved doses if there are no unacceptable toxicities and there is documented evidence of efficacy such as lack of disease progression.
Additional doses beyond the FDA-approved number of doses will require a new Prior Authorization request and review.

**Prior Authorization Information**

**Inpatient**
- For services described in this policy, precertification/preauthorization is required for all products if the procedure is performed inpatient.

**Outpatient**
- For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient.

<table>
<thead>
<tr>
<th>Product</th>
<th>Prior Authorization Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>Prior authorization is required.*</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>Prior authorization is required.*</td>
</tr>
<tr>
<td>Medicare HMO BlueSM</td>
<td>Prior authorization is required.*</td>
</tr>
<tr>
<td>Medicare PPO BlueSM</td>
<td>Prior authorization is required.*</td>
</tr>
</tbody>
</table>

Prior Authorization Request Form: Elzonris (tagraxofusp-erzs) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This form must be completed and faxed to: Medical and Surgical: 1-888-282-0780; Medicare Advantage: 1-800-447-2994.

[Click here for Elzonris (tagraxofusp-erzs) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) prior authorization form, # 928](#)

**CPT Codes / HCPCS Codes / ICD Codes**

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria must be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

**HCPCS Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9269</td>
<td>Injection, tagraxofusp-erzs, 10 microgram</td>
</tr>
</tbody>
</table>

**ICD-10 Procedure Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>XW033Q5</td>
<td>Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5</td>
</tr>
<tr>
<td>XW043Q5</td>
<td>Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5</td>
</tr>
</tbody>
</table>
**Description**

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a hematologic cancer that is caused by a malignant spread of plasmacytoid dendritic cells. These cells produce a large group of proteins called type 1 interferon that are responsible for regulating the immune system. In BPDCN, the overproduction of these cells results in an inflammatory immune response causing overexpression of interleukin-3 receptors (CD123). The overexpression of CD123 results in malignant growths on the skin which can appear in various shapes, sizes and colors. The disease may also progress to internal organs such as the lymph nodes, spleen, and central nervous system.

BPDCN is an aggressive cancer currently categorized as a subtype of high-risk acute myeloid leukemia. BPDCN is a rare condition representing less than 1% of acute myeloid cases and is most often diagnosed in males between 50-60 years old. The exact cause and prevalence of the disease is not yet understood. Current treatment options include intensive chemotherapy and hematopoietic stem cell transplantation. Clinical response rates and tolerability for current standards of care varies between patients. BPDCN is a fatal disease with a median survival rate of 8-14 months.

Elzonris is the first and only drug approved by the FDA for the treatment of BPDCN and has been evaluated in patients 2 years and older with relapsed/refractory and treatment naïve disease. Elzonris targets the CD123 receptors causing cell death by prohibiting protein synthesis. Common adverse events include hypoalbuminemia and capillary leak syndrome which can be fatal. Patients are infused with Elzonris on days 1-5 of a 21-day treatment cycle and can receive multiple treatment cycles each year.

**Summary**

For individuals with BPDCN, the evidence includes a 4-stage, non-randomized, multicenter study evaluating complete response rates and duration of response after treatment with Elzonris. The study includes both treatment naïve or refractory/relapsed patients. Complete response rates were measured by the absence of skin lesions and lack of lesions for areas where systemic/multisystemic disease was initially observed, and clinical complete response were defined as complete response with some evidence of skin abnormality not associated with prior skin lesions resulting from active disease.

Of the 47 patients included, 32 patients with BPDCN received Elzonris as a first line treatment and 21 patients (72%) achieved complete response. Almost half of those patients went on to receive stem cell transplant after treatment with Elzonris. The second group of patients included 15 individuals with relapsed or refractory disease with 67% achieving a complete response rate. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
</table>

**Information Pertaining to All Blue Cross Blue Shield Medical Policies**

Click on any of the following terms to access the relevant information:

- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

**References**


Endnotes

1 Based on expert opinion